Crescent Grove Advisors LLC Takes Position in DexCom, Inc. (NASDAQ:DXCM)

Crescent Grove Advisors LLC bought a new stake in shares of DexCom, Inc. (NASDAQ:DXCM) during the 4th quarter, HoldingsChannel reports. The firm bought 2,667 shares of the medical device company’s stock, valued at approximately $207,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Blue Whale Capital LLP grew its position in DexCom by 91.9% in the third quarter. Blue Whale Capital LLP now owns 236,000 shares of the medical device company’s stock valued at $15,821,000 after acquiring an additional 113,000 shares in the last quarter. Taylor Frigon Capital Management LLC boosted its stake in shares of DexCom by 51.6% in the third quarter. Taylor Frigon Capital Management LLC now owns 32,554 shares of the medical device company’s stock valued at $2,182,000 after purchasing an additional 11,075 shares during the period. Brooktree Capital Management purchased a new stake in DexCom during the 3rd quarter worth $683,000. National Pension Service lifted its holdings in DexCom by 4.1% in the 3rd quarter. National Pension Service now owns 949,743 shares of the medical device company’s stock worth $63,671,000 after buying an additional 37,363 shares in the last quarter. Finally, Intact Investment Management Inc. purchased a new position in DexCom in the 3rd quarter valued at about $650,000. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Price Performance

Shares of DXCM opened at $88.75 on Monday. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. The company has a market cap of $34.67 billion, a P/E ratio of 53.14, a PEG ratio of 2.23 and a beta of 1.12. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00. The stock has a fifty day moving average price of $79.50 and a 200 day moving average price of $77.12.

Insider Transactions at DexCom

In other news, EVP Sadie Stern sold 4,259 shares of the business’s stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total transaction of $318,275.07. Following the completion of the transaction, the executive vice president now directly owns 71,192 shares in the company, valued at approximately $5,320,178.16. The trade was a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 0.30% of the company’s stock.

Wall Street Analyst Weigh In

DXCM has been the topic of several recent analyst reports. Citigroup boosted their price target on DexCom from $85.00 to $91.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Oppenheimer reduced their target price on DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. Royal Bank of Canada dropped their price target on shares of DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. StockNews.com downgraded shares of DexCom from a “buy” rating to a “hold” rating in a research note on Saturday, November 2nd. Finally, Leerink Partners dropped their target price on shares of DexCom from $90.00 to $87.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. Five equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $99.29.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.